Discovery of novel PTP1B inhibitors via pharmacophore-oriented scaffold hopping from Ertiprotafib

Bioorg Med Chem Lett. 2013 Dec 1;23(23):6217-22. doi: 10.1016/j.bmcl.2013.10.002. Epub 2013 Oct 8.

Abstract

An integrated molecular design strategy combining pharmacophore recognition and scaffold hopping was exploited to discover novel PTP1B inhibitors based on the known PTP1B inhibitor Ertiprotafib. A composite pharmacophore model was proposed from the interaction mode of Ertiprotafib, and 21 diverse molecules from five distinct structural classes were designed and synthesized accordingly. New compounds with considerable inhibition against PTP1B were identified from each series, and the most active compound 3a showed IC50 value of 1.3 μmol L(-1) against human recombinant PTP1B. Docking study indicated that the new inhibitors assumed binding modes similar to that of Ertiprotafib.

Keywords: Ertiprotafib; PTP1B inhibitors; Pharmacophore; Scaffold hopping.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Drug Design
  • Enzyme Inhibitors / chemical synthesis
  • Enzyme Inhibitors / chemistry*
  • Enzyme Inhibitors / pharmacology*
  • Humans
  • Models, Molecular
  • Phenylpropionates / chemical synthesis
  • Phenylpropionates / chemistry*
  • Phenylpropionates / pharmacology*
  • Protein Tyrosine Phosphatase, Non-Receptor Type 1 / antagonists & inhibitors*
  • Thiophenes / chemical synthesis
  • Thiophenes / chemistry*
  • Thiophenes / pharmacology*

Substances

  • Enzyme Inhibitors
  • Phenylpropionates
  • Thiophenes
  • ertiprotafib
  • PTPN1 protein, human
  • Protein Tyrosine Phosphatase, Non-Receptor Type 1